Formulation and evaluation of Candesartan cilexetil nanosuspension for oral drug delivery system
Abstract
Nanocrystals are small particles whose size typically range from 1 to 100 nm. Nanocrystal-based nanosuspension is a drug delivery technique that involves incorporating drug nanocrystals into a nanosuspension matrix. The nanocrystal-based nanosuspension approach can be particularly useful for drugs with poor solubility or low bioavailability. The current study aimed to develop and characterize a nanocrystals-based nanosuspension of Candesartan cilexetil (CC). In the preparation, CC loaded nanosuspension was prepared employing Eudragit RLPO and PVA as a stabilizer by using solvent precipitation method. The drug content (%), DR (%) and zeta potential are performed for all formulations. The optimized formulation (CCSD2) had a particle size of 221 nm, a zeta potential of 30.4 mv, and a drug release rate of 95.58%, and it was used for further testing. The optimized formulation had a polydispersity index (PDI) of 0.218. SEM revealed drug nanocrystals agglomeration, which could have been caused by the water removal process. DSC showed a minor change in crystallinity, which could be attributed to the presence of lactose. The stability trial lasted 6 months. The solvent precipitation method is an efficient way to create CC nanocrystal with lower particle size. DSC thermogram confirmed no interaction between drug and excipients. The DR release study of CC nanosizing method. CC are efficiently and successfully confined inside the polymer. CC and other class II medicines may therefore find a promising carrier in the nanocrystal method.
Keywords:
Nanocrystal, Candesartan cilexetil, Eudragit RLPO, oral bioavailabilityDOI
https://doi.org/10.25004/IJPSDR.2025.170206References
Aly UF, Sarhan HA-M, Ali T F S, Sharkawy H A E B. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Drug Des Devel Ther. 2020;14:1851–1865. Available from: DOI: 10.2147/DDDT.S248511.
Al-Edresi S, Hamrah KA, Al-Shaibani A. Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. J Pharmacia. 2024;71:1-13. Available from: DOI: https://doi.org./10.3897/pharmacia.71.e114943.
Poudel S, Kim DW. Developing pH-modulated spray dried amorphous solid dispersion of candesartan cilexetil with enhanced in vitro and in vivo performance. Pharmaceutics. 2021;13(4):497. Available from: https://doi.org/10.3390/pharmaceutics13040497
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23(2):395-404. Available from: DOI: 10.3109/10717544.2014.914986
Surampalli G, Nanjwade BK, Patil PA, Chilla R. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. Drug Deliv. 2016;23(7):2124-38. Available from: doi: 10.3109/10717544.2014.945017.
Kamble SS, Gambhire MS, Gujar KN. Optimization and development of candesartan cilexetil loaded solid lipid nanoparticle for the treatment of hypertension. J Pharm Biosci. 2015;3:53-64.
Albaidhani SF, Hussein AA. Preparation and evaluation of solid supersaturable self-nanoemulsifying drug delivery system of candesartan cilexetil. J Pharm Sci and Res. 2019;11(3):859-68.
Diwan R, Ravi PR, Pathare NS, Aggarwal V. Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. Colloids Surf B Biointerfaces. 2020;193:111073. Available from: DOI: 10.1016/j.colsurfb.2020.111073.
AboulFotouh K, Allam AA, El-Badry M, El-Sayed AM. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil. Eur J Pharm Sci. 2017;109:503-513. Available from: doi: 10.1016/j.ejps.2017.09.001.
Guan H, Wang M, Yu S, Wang C, Chen Q, Chen Y, Zhang W, Fan J. Candesartan Cilexetil Formulations in Mesoporous Silica: Preparation, Enhanced Dissolution In Vitro, and Oral Bioavailability In Vivo. J Pharm Sci. 2024;113(10):3045-53. Available from: DOI: 10.1016/j.xphs.2024.07.007.
Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm. 2011;79(3):635-51. Available from: DOI: 10.3797/scipharm.1103-17.
AboulFotouh K, Allam AA, El-Badry M, El-Sayed AM. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation. J Pharm Sci. 2019;108(11):3599-3608. Available from:doi: 10.1016/j.xphs.2019.07.004.
Vantimita SR, Jeganath S. Formulation and evaluation of gastro retentive drug delivery system of candesartan cilexetil. Int J Health Sci. 2022;6(1):5093–5106. Available from:https://doi.org/10.53730/ijhs.v6nS1.6150
Mady OY, Abulmeaty MMA, Donia AA, Al-Khureif AA, Al-Shoubki AA, Abudawood M, Abdel Moety DA. Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats. Membranes. 2021;11(9):659. Available from: DOI: 10.3390/membranes11090659
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23(2):395-404. Available from: DOI: 10.3109/10717544.2014.914986
Jain S, Reddy VA, Arora S, Patel K. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Drug Deliv Transl Res. 2016;6(5):498-510. Available from: doi: 10.1007/s13346-016-0297-8.
Surampalli G, Nanjwade BK, Patil PA, Chilla R. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. Drug Deliv. 2016;23(7):2124-2138. Available from: doi: 10.3109/10717544.2014.945017.
Ali HH, Hussein AA. Oral nanoemulsions of candesartan cilexetil: formulation, characterization and in vitro drug release studies. AAPS Open. 2017;3(4):1-16.
Anwar W, Dawaba HM, Afouna MI, Samy AM, Rashed MH, Abdelaziz AE. Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration. Pharmaceutics. 2020;12(11):1047. Available from: doi: 10.3390/pharmaceutics12111047.
Samanthula KS, Bairi AG, Mahendra Kumar C. Muco-adhesive buccal tablets of candesartan cilexetil for oral delivery: preparation, in-vitro and ex-vivo evaluation. J Drug Delivery Ther. 2021;11(1):35-42.
Das S, Suresh P, Deshmukh R. Design of eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomed Nanotech Bio Medi. 2010;6:318-323. Available from: https://doi.org/10.1016/j.nano.2009.09.002
Anwar W, Dawaba HM, Afouna MI, Samy AM, Rashed MH, Abdelaziz AE. Enhancing the oral bioavailability of candesartan cilexetil loaded nanostructured lipid carriers: In vitro characterization and absorption in rats after oral administration. Pharmaceutics. 2020; 12(11):1047. Available from: doi: 10.3390/pharmaceutics12111047.
Bisht T, Bolmal UB, Nainwal N. Formulation of Candesartan Cilexetil Nanoparticles by Ionotropic Gelation Method Using Ultrasonication. Ind J Pharm Edu Res. 2023;57(3):728-35.
Khanfar M, Taani B AL, Mohammad E. Enhancement of dissolution and stability of candesartan cilexetil–loaded silica polymers. Int J App Pharm. 2019;11(2):64-70. Available from: DOI:10.22159/ijap.2019v11i2.30411.
Fouad AG, Ali MR, Naguib DM, Farouk HO, Zanaty MI, El-Ela FI. Design, optimization, and in vivo evaluation of invasome-mediated candesartan for the control of diabetes-associated atherosclerosis. Drug Deliv Transl Res. 2024;14(2):474-90. Available from: doi: 10.3390/ph18010031
Yiyan MO, Jingmeng SU, Chenchen FA, Zhenzhen JI, Xin ZH, Weiyu ZH. Construction and Characterization of Candesartan Cilexetil P123/F127 Mixed Micelle Delivery System. Herald of Medicine. 2022;41(12):1828-35. Available from: doi: 10.1080/03639045.2023.2293122.
Mady OY, Abulmeaty MM, Donia AA, Al-Khureif AA, Al-Shoubki AA, Abudawood M, Abdel Moety DA. Formulation and bioavailability of novel mucoadhesive buccal films for candesartan cilexetil in rats. Membranes. 2021;11(9):659. Available from: doi: 10.3390/membranes11090659
Awadeen RH, Boughdady MF, Meshali MM. Quality by design approach for preparation of zolmitriptan/chitosan nanostructured lipid carrier particles–formulation and pharmacodynamic assessment. Int J Nanomedicine. 2020;15:8553-68. Available from: doi: 10.2147/IJN.S274352.
Jain S, Patel K, Arora S, Reddy VA, Dora CP. Formulation, optimization, and in vitro–in vivo evaluation of olmesartan medoxomil nanocrystals. Drug Deliv Transl Res. 2017;7(2):292-303. Available from: DOI: 10.1007/s13346-016-0355-2
Hezha AA, Hunar KO. Solubility Enhancement of a Poorly Water-Soluble Drug Using Hydrotropy and Mixed Hydrotropy-Based Solid Dispersion Techniques. Hindawi Advances in Pharmacological and Pharmaceutical Sciences. 2022;2022:7161660. Available from: doi: 10.1155/2022/7161660.
Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Alharbi KS, Yasir M, Elmowafy M, Mohammed EF, Al-Oanzi ZH. Formulation of chitosan-coated piperine NLCs: Optimization, in vitro characterization, and in vivo preclinical assessment. AAPS PharmSciTech. 2021;22(7):1-6. Available from: doi: 10.1208/s12249-021-02098-4.
Yuksel N, Bayindir ZS, Aksakal E, Ozcelikay AT. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: in vitro and in vivo evaluations. Int J Biol Macromol. 2016;82:453-63. Available from: doi: 10.1016/j.ijbiomac.2015.10.019.
Harish V, Tewari D, Mohd S, Govindaiah P, Babu MR, Kumar R, Gulati M, Gowthamarajan K, Madhunapantula SV, Chellappan DK, Gupta G. Quality by design-based formulation of xanthohumol loaded solid lipid nanoparticles with improved bioavailability and anticancer effect against PC-3 cells. Pharmaceutics. 2022;14(11):2403. Available from: doi: 10.3390/pharmaceutics14112403.
Madan JR, Patil K, Awasthi R, Dua K. Formulation and evaluation of solid self-microemulsifying drug delivery system for azilsartan medoxomil. International Journal of Polymeric Materials and Polymeric Biomaterials. 2021;70(2):100-16. Available from: DOI:10.1080/00914037.2019.1695206
Sharma S, Sharma JB, Bhatt S, Kumar M. Optimization and fabrication of curcumin loaded solid lipid nanoparticles using box-Behnken design for nasal delivery. Nanoscience and Nanotechnology-Asia. 2022;12(6):7-18. Available from: DOI: 10.2174/2210681213666221103151333
El-Housiny S, Fouad AG, El-Bakry R, Zaki RM, Afzal O, El-Ela FI, Ghalwash MM. In Vitro and in vivo characterization of nasal pH-Responsive in-situ hydrogel of Candesartan-loaded invasomes as a potential stroke treatment. Drug Deliv Transl Res. 2024;1-20. Available from: doi: 10.1007/s13346-024-01700-z.
Abla KK, Mneimneh AT, Allam AN, Mehanna MM. Application of Box-Behnken design in the preparation, optimization, and in-vivo pharmacokinetic evaluation of oral tadalafil-loaded niosomal film. Pharmaceutics. 2023;15(1):173. Available from: doi: 10.3390/pharmaceutics15010173.
Patel K, Patel J, Shah S. Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy. AAPS PharmSciTech. 2023;24(7):186. Available from: doi: 10.1208/s12249-023-02642-4.
Jain S, Reddy VA, Arora S, Patel K. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Drug Deliv Transl Res. 2016;6(5):498-510. Available from: doi: 10.1007/s13346-016-0297-8.
Published
Abstract Display: 83 
PDF Downloads: 43 How to Cite
Issue
Section
Copyright (c) 2025 Mrs. Sonali Vijaykumar Magdum, Dr. Pramodkumar Jaykumar Shirote
This work is licensed under a Creative Commons Attribution 4.0 International License.
